Pyrrolotriazine inhibitors of kinases

Details Pyrrolotriazine inhibitors of kinases Pyrrolotriazine inhibitors of kinases

2007-07-17

2007-07-17

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S183000

Reexamination Certificate

active

11345845

ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

REFERENCES:
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Mass, R.D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.

Affiliated with

Also associated with

Rating

Pyrrolotriazine inhibitors of kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolotriazine inhibitors of kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolotriazine inhibitors of kinases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3751141